NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Geron Corporation GERN
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.13
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-33.0%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 17-year series below
Revenue
Net income
Per share
USD -0.13
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-33.0%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-14.3%
Each USD of equity lost 33 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−26.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.2%
−26.0%
−15.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.64B
Shares outstanding, FY2025
Change, 5 years+106.0%
Change, 10 years—
The share count grew 106% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 570.5M
total assets, end of FY2025
Total assetsUSD 570.5M
EquityUSD 225.9M
CashUSD 77.6M
Gross debtUSD 119.5M
Net debtUSD 42.0M
Current ratio4.66×
Net debt stands at 19% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
EBITDA $B
·
·
·
·
·
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
·
Income tax $B
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.1
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
EPS, diluted $
−0.13
−0.27
−0.32
−0.37
−0.35
−0.28
−0.36
−0.15
−0.18
−0.19
0.00
−0.23
−0.30
−0.54
−0.78
−1.14
−0.80
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
0
−0
−0
·
·
·
·
ROE %
−33.0
−66.1
−112.3
−137.5
−68.8
−43.7
−43.8
−19.2
−24.7
−22.3
0.0
−37.5
−52.8
−59.3
−57.1
−61.0
−40.7
Shares out B
0.64
0.61
0.54
0.39
0.32
0.31
0.20
0.19
0.16
0.16
0.16
0.16
0.13
0.13
0.13
0.12
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed